Second, VEGF is a potent immunomodulator acting in part through direct effects on T cells, a xenograft model has limited predictive power to evaluate how anti-VEGF/CD47 therapeutic combinations would regulate tumor growth in immune competent mice or humans. Here, CD47 is linked to neoplasm.